<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001067'>Neurofibromatosis</z:hpo> type 1 is a common multisystemic disorder that can result in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> of the central and peripheral <z:mp ids='MP_0008912'>nervous</z:mp> system </plain></SENT>
<SENT sid="1" pm="."><plain>Individuals with <z:hpo ids='HP_0001067'>neurofibromatosis</z:hpo> type 1 are also at increased risk to develop <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya syndrome</z:e>, which is a cerebrovascular condition that predisposes affected individuals to develop <z:hpo ids='HP_0001297'>strokes</z:hpo> as a result of progressive narrowing of the intracranial internal carotid arteries and failure of adequate blood supply through collateral vessels </plain></SENT>
<SENT sid="2" pm="."><plain>We report a case of a young boy with <z:hpo ids='HP_0001067'>neurofibromatosis</z:hpo> type 1 with <z:hpo ids='HP_0100843'>glioblastoma</z:hpo> who developed <z:hpo ids='HP_0003678'>rapidly progressive</z:hpo> <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya</z:e> vasculopathy after treatment with the <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> inhibitor bevacizumab </plain></SENT>
</text></document>